<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02213471</url>
  </required_header>
  <id_info>
    <org_study_id>BX001</org_study_id>
    <nct_id>NCT02213471</nct_id>
  </id_info>
  <brief_title>Patient Preference for Biopsy Notification</brief_title>
  <official_title>Patient Preference for Biopsy Notification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Wei</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      Effective communication between physician and patient is fundamental to effective care. The&#xD;
      recent introduction of electronic patient on-line portals has the potential to change the&#xD;
      communication landscape. The investigators surveyed patients to assess their preferred&#xD;
      modality for biopsy notification at 3 institutions with differing patient access to on-line&#xD;
      portals, to ascertain what patient preferences are currently and if it has changed from&#xD;
      historical preferences. Our hypothesis is that as patients become more familiar with ln-line&#xD;
      portals, their preferences will likely reflect familiarity with this modality.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient preference for biopsy notification</measure>
    <time_frame>1 year</time_frame>
    <description>Patients were asked to rank in order of preference their preferred method for being notified of a skin biopsy result</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">301</enrollment>
  <condition>Elevated Risk for Melanoma</condition>
  <arm_group>
    <arm_group_label>Elevated risk for melanoma</arm_group_label>
    <description>Individuals at increased risk for melanoma due to past history of melanoma, family history of melanoma, the presence of many moles, the presence of a genetic mutation known to increase the risk of melanoma.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals at increased risk for melanoma due to past history of melanoma, family history&#xD;
        of melanoma, the presence of many moles, the presence of a genetic mutation known to&#xD;
        increase the risk of melanoma. Individuals were followed in a Pigmented Lesion Clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who were 18 years of age or older and English speaking were eligible to&#xD;
             participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Younger than 18, non-English speaking.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria L Wei, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 7, 2014</study_first_submitted>
  <study_first_submitted_qc>August 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2014</study_first_posted>
  <last_update_submitted>August 8, 2014</last_update_submitted>
  <last_update_submitted_qc>August 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Maria Wei</investigator_full_name>
    <investigator_title>Associate Professor of Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02213471
org study id: BX001
nct id: NCT02213471
lead sponsor: 
Effective communication between physician and patient is fundamental to effective care. The
      recent introduction of electronic patient on-line portals has the potential to change the
      communication landscape. The investigators surveyed patients to assess their preferred
      modality for biopsy notification at 3 institutions with differing patient access to on-line
      portals, to ascertain what patient preferences are currently and if it has changed from
      historical preferences. Our hypothesis is that as patients become more familiar with ln-line
      portals, their preferences will likely reflect familiarity with this modality.
observational model: Cohort
time perspective: Prospective
measure: Patient preference for biopsy notification
time frame: 1 year
description: Patients were asked to rank in order of preference their preferred method for being notified of a skin biopsy result
arm group label: Elevated risk for melanoma
description: Individuals at increased risk for melanoma due to past history of melanoma, family history of melanoma, the presence of many moles, the presence of a genetic mutation known to increase the risk of melanoma.
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Maria L Wei, MD PhD
role: Principal Investigator
affiliation: University of California, San Francisco
facility: 
country: United States
responsible party type: Sponsor-Investigator
investigator affiliation: University of California, San Francisco
investigator full name: Maria Wei
investigator title: Associate Professor of Dermatology
mesh term: Melanoma